T
Tetsuya Ohtaki
Researcher at Takeda Pharmaceutical Company
Publications - 122
Citations - 6899
Tetsuya Ohtaki is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Receptor & Peptide. The author has an hindex of 33, co-authored 122 publications receiving 6454 citations.
Papers
More filters
Journal ArticleDOI
Design and Synthesis of an Investigational Nonapeptide KISS1 Receptor (KISS1R) Agonist, Ac-d-Tyr-Hydroxyproline (Hyp)-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH2 (TAK-448), with Highly Potent Testosterone-Suppressive Activity and Excellent Water Solubility
Naoki Nishizawa,Yoshihiro Takatsu,Satoshi Kumano,Atsushi Kiba,Junko Ban,Shunichirou Tsutsumi,Hisanori Matsui,Shin-ichi Matsumoto,Masashi Yamaguchi,Yukihiro Ikeda,Masami Kusaka,Tetsuya Ohtaki,Fumio Itoh,Taiji Asami +13 more
TL;DR: The optimization studies of metastin derivatives led to the discovery of 1, which suppressed plasma testosterone in rats at lower doses than those of leuprolide, and substitution with cyclic amino acids, which could change peptide conformation, retained its potency.
Journal ArticleDOI
Design and synthesis of ETA receptor antagonists and study of ETA receptor distribution
Chieko Kitada,Tetsuya Ohtaki,Yasushi Masuda,Yoshinori Masuo,Hiromi Nomura,Taiji Asami,Yoshio Matsumoto,Mioko Satou,Masahiko Fujino +8 more
TL;DR: Autoradiographic studies showed that ETA receptors are most abundant in the cardiac muscle, intestine, large bowel, spleen, and testis.
Patent
Human and murine galanin receptor
TL;DR: Galanin receptor proteins, production and use thereof including screening of galanin receptor agonists and antagonists are provided in this article, where it is allowable to efficiently screen a Galin receptor receptor agonist or antagonist by using the Galin-RBP protein, the partial peptide thereof, the galin receptor protein encoding DNA, the receptor protein-containing cell or its membrane fraction.
Journal ArticleDOI
A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
Hiroshi Inooka,Kotaro Sakamoto,Tokuyuki Shinohara,Yasushi Masuda,Michiko Terada,Satoshi Kumano,Kotaro Yokoyama,Jiro Noguchi,Naoki Nishizawa,Hidenori Kamiguchi,Hisashi Fujita,Taiji Asami,Shiro Takekawa,Tetsuya Ohtaki +13 more
TL;DR: The results suggest that 15 (NMU-0002), which showed potent and long-lasting biological profiles in vivo, represents a candidate peptide for investigating the central and peripheral actions of NMU and its potential for clinical use.
Patent
Metastin derivative and use thereof
Chieko Takeda Pharm. Co. Ltd. Kitada,Taiji Asami,Naoki Nishizawa,Tetsuya Ohtaki,Naoki Takeda Pharm. Co. Ltd. Tarui,Hirokazu Matsumoto,Jiro Noguchi,Hisanori Matsui +7 more
TL;DR: In this article, a stable metastin derivative having excellent biological activities (i.e., a cancer metastasis-inhibiting activity, a cancer proliferation-and a gonadotropin secretion-promoting activity, and a sex hormone secretion-enhancing activity) was proposed.